Shigella WRSS1 Vaccine Trial in Bangladesh

PATH

Status and phase: Completed; Phase 1

Conditions: Diarrhea

Treatments: Biological: Shigella sonnei Strain WRSS1 Vaccine; Biological: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT02934178

VAC-049

Details and patient eligibility

About

This is a research study of an experimental (investigational) live attenuated Shigella sonnei vaccine (WRSS1) to find a dose of the vaccine that is safe, tolerable, and develops an immune response. Shigella causes bloody and watery diarrhea, and infants and children living in developing countries experience the greatest consequences of this disease.

Full description

The WRSS1 vaccine in will be given to healthy toddlers (12-24 months old). The first vaccination was given to toddlers in the inpatient unit and the second and third doses will be administered on an outpatient basis. A safety evaluation was performed after the first dose before enrolling subjects in subsequent cohorts to receive a higher vaccine dose.

After the study was initiated, its funder, the Bill and Melinda Gates Foundation (BMGF) made significant changes to the PATH Enteric Vaccine Initiative (EVI) portfolio and decided not to support the three higher-dose cohorts (Cohort 1, 2, and 3) planned as part of this study.

Enrollment: 16 patients

Sex: All

Ages: 12 to 24 months old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Male or female children aged between 12 to 24 month of age at the time of vaccination
2. General good health as determined by the screening evaluation no greater than 30 days before admission
3. Father, mother or other legally acceptable representative (guardian) properly informed about the study, able to understand it and sign the informed consent form
4. Normal bowel habits (< 3 grade 1 or 2 stools each day; ≥ 1 grade 1 or 2 stools every 2 days)
5. Free of obvious health problems as established by medical history and clinical examination before entering into the study.
6. Parent or guardian available for the entire period of the study and reachable by study staff throughout the entire follow-up period.
7. Signed Informed Consent from the Parent or legal guardian

Exclusion criteria

1. Presence of a significant medical that in the opinion of the Investigator precludes participation in the study
2. Known infection with human immunodeficiency virus (HIV)
3. Presence in the serum of hepatitis A virus (HAV) or hepatitis C virus (HCV) antibody.
4. History of congenital abdominal disorders, intussusception, abdominal surgery or any other congenital disorder.
5. Participation in research involving another investigational product (defined as receipt of investigational product) 30 days before planned date of first vaccination or concurrently participating in another clinical study, at any time during the study period, in which the child has been or will be exposed to an investigational or a non-investigational product
6. Clinically significant abnormalities on physical examination
7. Clinically significant abnormalities in screening hematology, serum chemistry as determined by the PI or the PI in consultation with the Study Physician
8. History of febrile illness within 48 hours prior to vaccination
9. Known or suspected impairment of immunological function based on medical history and physical examination
10. Prior receipt of any Shigella vaccine
11. Fever at the time of immunization. Fever is defined as a temperature ≥ 37.5C (99.5F) on axillary, oral, or tympanic measurement
12. History of known shigellosis, chronic diarrhea/dysentery in the past 2 months
13. Current use of iron or zinc supplements within the past 7 days; current use of antacids (H2 blockers, omeprazol, OTC agents) or immunosuppressive drug
14. Allergy to quinolone, sulfa, and penicillin classes of antibiotics
15. Clinical evidence of active gastrointestinal illness
16. Prior receipt of a blood transfusion or blood products, including immunoglobulins
17. Presence of any significant systemic disorder (cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological, cancer or autoimmune disease) as determined by medical history and/or physical examination which would endanger the participant's health or is likely to result in non-conformance to the protocol.
18. History of any neurologic disorders or seizures.
19. Acute disease at the time of enrolment
20. Medically significant malnutrition, defined as moderate malnutrition (wt-for-age z-score between -3.0 and -2.0) and severe malnutrition (wt-for-age z-score <-3.0 or edema)
21. Any conditions which, in the opinion of the investigator, might jeopardize the safety of study participants or interfere with the evaluation of the study objectives
22. Receipt of antimicrobial drugs for any reason or a fever ≥ 38C within 7 days before vaccination
23. History of diarrhea during the 7 days before vaccination.
24. Has any household member(s) who is immunocompromised or under the age of 1 year old.
25. Culture or polymerase chain reaction (PCR) positive for any Shigella strain

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

16 participants in 8 patient groups, including a placebo group

Cohort 1: WRSS1 3 x 10³ CFU

Experimental group

Description:

Healthy toddlers receiving 3 oral doses of 3 x 10³ colony-forming units (CFU) of Shigella sonnei Strain WRSS1 approximately 4 weeks apart.

Treatment:

Biological: Shigella sonnei Strain WRSS1 Vaccine

Cohort 2: WRSS1 3 x 10⁴ CFU

Experimental group

Description:

Healthy toddlers receiving 3 oral doses of 3 x 10⁴ CFU of Shigella sonnei Strain WRSS1 approximately 4 weeks apart.

Treatment:

Biological: Shigella sonnei Strain WRSS1 Vaccine

Cohort 3: WRSS1 3 x 10⁵ CFU

Experimental group

Description:

Healthy toddlers receiving 3 oral doses of 3 x 10⁵ CFU of Shigella sonnei Strain WRSS1 approximately 4 weeks apart.

Treatment:

Biological: Shigella sonnei Strain WRSS1 Vaccine

Cohort 4: WRSS1 3 x 10⁶ CFU

Experimental group

Description:

Healthy toddlers receiving 3 oral doses of 3 x 10⁶ CFU of Shigella sonnei Strain WRSS1 approximately 4 weeks apart.

Treatment:

Biological: Shigella sonnei Strain WRSS1 Vaccine

Cohort 1: Placebo

Placebo Comparator group

Description:

Healthy toddlers receiving 3 oral doses of placebo to match 3 x 10³ WRSS1 approximately 4 weeks apart.

Treatment:

Biological: Placebo

Cohort 2: Placebo

Placebo Comparator group

Description:

Healthy toddlers receiving 3 oral doses of placebo to match 3 x 10⁴ WRSS1 approximately 4 weeks apart.

Treatment:

Biological: Placebo

Cohort 3: Placebo

Placebo Comparator group

Description:

Healthy toddlers receiving 3 oral doses of placebo to match 3 x 10⁵ WRSS1 approximately 4 weeks apart.

Treatment:

Biological: Placebo

Cohort 4: Placebo

Placebo Comparator group

Description:

Healthy toddlers receiving 3 oral doses of placebo to match 3 x 10⁶ WRSS1 approximately 4 weeks apart.

Treatment:

Biological: Placebo